Linvoseltamab
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Systemic Light Chain Amyloidosis
Conditions
Relapsed/Refractory Systemic Light Chain Amyloidosis
Trial Timeline
Aug 7, 2024 → Feb 20, 2035
NCT ID
NCT06292780About Linvoseltamab
Linvoseltamab is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Relapsed/Refractory Systemic Light Chain Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06292780. Target conditions include Relapsed/Refractory Systemic Light Chain Amyloidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07181941 | Phase 1/2 | Recruiting |
| NCT06140524 | Phase 2 | Recruiting |
| NCT06376526 | Phase 2 | Recruiting |
| NCT06292780 | Phase 1/2 | Recruiting |
| NCT05955508 | Phase 2 | Active |
| NCT05828511 | Phase 1/2 | Recruiting |
| NCT03761108 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Systemic Light Chain Amyloidosis